The 180-Day Suspension and the Expired Hood Certificate
A Minnesota community pharmacy compounds two products in the same week. First, an omeprazole 2 mg/mL oral suspension for a 9-month-old, made from opened omeprazole capsules, simple syrup, and sterile water. There is no preservative in the formula, no stability study on file, and the technician's draft label reads 'Discard 180 days after preparation. Store at room temperature.' Second, the cleanroom prepares 40 syringes of cefazolin 50 mg/mL for a local surgery center. While revising policy, the pharmacist-in-charge discovers the ISO Class 5 hood was last certified 14 months ago, that 12 of the cefazolin syringes were released to the surgery center last week, and that the written SOPs, last revised in 2019, still cite superseded versions of USP <795> and <797>. On Friday the surgery center calls asking for the remaining 28 syringes.
1. What beyond-use date may be assigned to the omeprazole suspension, and what is the reasoning?
Read the worked answer
The 180-day figure is wrong on two independent grounds.
- Classification. The preparation is an aqueous dosage form and it is preservative-free. Under the default beyond-use date framework in USP <795>, the long (roughly six-month) default applies to nonaqueous dosage forms. Aqueous preparations fall into much shorter defaults - a preservative-free aqueous preparation is measured in days under refrigeration, and a preserved aqueous preparation gets a longer but still limited window. A 180-day, room-temperature BUD does not exist for this product.
- Ceiling rule. No assigned BUD may exceed the earliest expiration date of any component, and a BUD longer than the default requires documented stability information (a study or a published reference specific to the formulation) placed in the compounding record.
Judgment points the technician missed:
- The word 'sterile water' does not make the finished suspension sterile or preserved.
- The default BUD table is a default, not a target. If the pharmacy cannot document stability, it uses the conservative default.
- The label must state the beyond-use date and storage conditions in addition to the ordinary prescription labeling elements - 'shake well' and 'refrigerate' belong on it too.
- For a 9-month-old, the prescriber and caregiver need realistic dating; a mislabeled 180-day room-temperature BUD invites a degraded or contaminated dose rather than a fresh one.
2. What must be done about the 12 cefazolin syringes already released and the 28 still in the pharmacy?
Read the worked answer
Treat the released doses as potentially non-sterile and act on that assumption.
- The 28 remaining syringes are not released. Quarantine them. A CSP cannot be shown to have been prepared under ISO Class 5 conditions when the primary engineering control's certification lapsed; the pharmacy cannot demonstrate the required air quality, and the assumed sterility assurance is gone.
- The 12 released syringes require a recall-type response: notify the surgery center immediately, identify which patients received doses if any were administered, notify the prescribers, and follow the pharmacy's adverse-event and recall procedure. Sterile compounding failures are patient-safety events, not inventory events.
- Do not compound sterile preparations again until the hood and the cleanroom are recertified (certification is required on a recurring basis, generally every six months, and after relocation or repair), personnel competency is re-verified, and the SOPs are rewritten to the current chapter versions.
- Document the whole episode in the continuous quality improvement record: what happened, who was notified, the corrective actions, and the timeline. A pattern of lapsed certification plus stale SOPs is exactly what a Board inspector will look for.
- Report as required. The pharmacist-in-charge should determine whether the event requires notification to the Board of Pharmacy and to the affected facility's quality office; when in doubt, notify.
3. What must appear on the label of the omeprazole suspension, and what records must support the batch?
Read the worked answer
Label (in addition to the ordinary prescription elements - patient name, drug, strength, quantity, directions, prescriber, pharmacy name/address/phone, prescription number, date):
- The beyond-use date, stated as a date, not a slogan
- Storage conditions (e.g., refrigerate)
- Handling instructions such as 'shake well'
- Any auxiliary warnings appropriate to the drug and the patient
- For a compounded preparation, the label must identify it as compounded and must not imply FDA approval of the formulation
Records that must exist for the batch:
- A master formulation record - the formula, components, quantities, equipment, compounding steps, and the basis for the assigned BUD
- A compounding record for the specific batch - who compounded it, when, the quantity made, and the components actually used with lot numbers and expiration dates
- Documentation of the BUD rationale (default table or a cited stability source)
- A final check by the pharmacist, recorded
Judgment point: if the pharmacy cannot produce the master formulation record and the BUD rationale on demand, it cannot defend the BUD it printed. That is a documentation failure that becomes a patient-safety failure.